ClinicalTrials.gg
RecruitingNCT07147296Empower BPUpdated Jun 16, 2026

ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury

An interventional study of ARC-IM System Implantation and ARC-IM Therapy (Group 1) in Spinal Cord Injuries and Blood Pressure Disorders, sponsored by ONWARD Medical, Inc.. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by ONWARD Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 968 studies in Spinal Cord Injuries with a site in United States — 249 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Planned enrollment
159th of 836
60 · median 24
Started
2025
with 56 others
No phase
601 of 968
189 open now
Primary completion
2026-11
later than 82 of 307 live
Registered
893rd of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 159th largest by planned enrollment of the 836 interventional ones that give a count, is one of 57 that started in 2025, is one of 601 with no phase, reaches primary completion later than 82 of the 307 other live ones, and was the 893rd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

249 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

Empower BP is a pivotal, interventional, multicenter, prospective, randomized, controlled double-blinded study to evaluate the safety and effectiveness of the ARC-IM System in managing symptomatic blood pressure instability in individuals with chronic SCI (>1 year after SCI).

The primary effectiveness outcome will be evaluated through subject-reported ADFSCI and seated blood pressure assessments at 3 months post-implant.

Following a baseline screening period and the surgical implantation of the ARC-IM System, subjects will be randomized with a 2:1 ratio into an active or control arm for 3 months. All the subjects will undergo therapy activation sessions (into either Group 1: active intervention, or Group 2: intervention aimed to mimic the active intervention without the active component) within 21 days of the surgical implant and will then commence independent at-home use of ARC-IM Therapy. At the 3 Month timepoint, after all assessments are conducted, all subjects will transition to the open-label period in order to receive the active version of the ARC-IM System in an open-label fashion. All subjects will undergo therapy programming sessions following Month 3.

03

Conditions studied

  • Spinal Cord Injuries
  • Blood Pressure Disorders
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or above, and no older than 75 years at the time of enrollment.
  2. Clinical evidence of Orthostatic Hypotension (blood pressure drop of 20mmHg systolic or 10mmHg diastolic) measured during Head Up Tilt Table assessment (HUTT, within 10 minutes) with current standard of care if any. 2 out of 3 tests must meet OH criteria.
  3. Clinical evidence of sustained hypotension (average systolic Blood pressure ≤ 110 mmHg) when measured each minute for 10 minutes while seated and in the absence of supportive compressive garments and medication.
  4. Evidence of symptomatic hypotension as determined by a non-zero OHSA total score
  5. A Spinal cord injury at the neurologic level between C2 and T6 inclusive.
  6. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D.
  7. Traumatic (non-progressive) chronic spinal cord injury with minimum 12 months post-injury prior to study entry.
  8. Average A-P diameter of the sponal canal ≥ 13 mm, measured on MRI at the disc space at level(s) planned for implantation
  9. Stable medical, physical, and psychological condition as considered by the investigators.
  10. Stable dose of blood pressure medication for 30-days prior to enrollment into the study . Stability will be defined as no changes to medication regimens based on treating physician instructions.
  11. Subjects who are on long-term antihypertensive treatment must discontinue these medications no less than 30 days prior to enrollment in the study. This requirement does not apply to antihypertensive agents administered for the acute management of autonomic dysreflexia (AD)
  12. If the subject requires daily continuous support from a personal caregiver, the presence of a caregiver during the study visits is mandatory.
  13. Willing and able to provide .
  14. Stated willingness to comply with all study procedures and availability for the duration of the study.
  15. Willing and able to comply with the instructions for use, operate the study devices, and comply with this clinical investigation plan

Exclusion criteria

Exclusion Criteria:

  1. Subject has an etiology of spinal cord dysfunction/injury.
  2. Subject has diseases and conditions that would increase the morbidity and mortality of the surgical procedures required by the study.
  3. Subject has a history of physiologic hypotension prior to SCI
  4. Subject has a history of unexpected blood pressure instability related to medications
  5. Inability to withhold antiplatelet/anticoagulation agents perioperatively.
  6. History of myocardial infarction or cerebrovascular event within the past 6 months. or
  7. History of chronic/recurrent severe cardiac arrythmias (e.g., ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block)
  8. Evidence of underlying cardiac conditions on Holter monitoring performed at screening including but not limited to arrhythmias (e.g., atrial fibrillation, ventricular tachycardia),
  9. Evidence of ischemic changes or prolonged (QTc > of 450 ms for males and 470 ms for females) identified on during screening,
  10. Subjects with a known diagnosis of heart failure, including but not limited to (NYHA) Class I-IV, or with evidence of clinically significant left ventricular dysfunction ( \< 40%) as determined by echocardiogram during screening or within the past 6 months,
  11. Current renal/kidney, hepatic, or other concomitant disorders deemed severe by the Investigator including those ones that could be linked to severe autonomic dysreflexia.
  12. Requires continuous ventilator support.
  13. Imaging (MRI, CT, X-ray) findings within the last 12 months that contraindicate lead placement
  14. Known allergic reaction to implanted materials
  15. Requires continuous/frequent/any transcutaneous spinal cord stimulation treatment.
  16. Has any active implanted medical device (e.g. baclofen pump, pacemaker).
  17. Inability to receive a pre-operative MRI.
  18. Female subject who is pregnant, breastfeeding or planning to become pregnant or breastfeed. Women of must have a negative pregnancy test completed at baseline visit per site standard test.
  19. Presence of pressure sore at time of screening or baseline graded stage 3 or 4 .
  20. Subject is enrolled or intends to participate in another clinical drug and/or device study or registry that may interfere with the results of this study, as determined by ONWARD Medical personnel.
  21. Presence of other anatomic or comorbid conditions, or other medical, social, or psychologic conditions such as severe uncontrolled neuropathic pain, depression, history of alcohol or substance abuse, history of schizophrenia or psychotic illness, severe personality disorder or other significant psychiatric or cognitive disorders that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group 1

    ARC-IM System with active stimulation since day 0

    Procedure: ARC-IM System Implantation · Device: ARC-IM Therapy (Group 1)

  • Sham comparator
    Group 2

    ARC-IM System without active stimulation before the open-label phase of the study

    Procedure: ARC-IM System Implantation · Device: ARC-IM Therapy (Group 2)

Interventions

  • ProcedureARC-IM System Implantation

    Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator

  • DeviceARC-IM Therapy (Group 1)

    The ARC-IM System is programmed since day 0 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury

  • DeviceARC-IM Therapy (Group 2)

    The ARC-IM System is programmed at month 3 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving a change in the hypotension domain of the ADFSCI short-form questionnaire

    Proportion of subjects achieving a reduction of ≥ 4 points in the hypotension domain of the ADFSCI short-form questionnaire compared to baseline

    Time frame: 3-months post-implant

  2. Proportion of subjects achieving elevation in SBP during seated BP test

    Proportion of subjects achieving an elevation of ≥ 10 mmHg in systolic blood pressure during the seated BP test with stimulation ON compared to stimulation OFF

    Time frame: 3-months post-implant

  3. Incidence of serious adverse device effects

    Description of all Serious Adverse Device Effects from ARC-IM System implant until Month 6

    Time frame: 6-months post-implant

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

Of 49 industry-sponsored interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 13 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 29, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Mar 2029
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07147296
Lead sponsor
ONWARD Medical, Inc.
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Oct 17, 2025
Primary completion
Nov 2026 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jun 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion